Study Protocol R1908-1909-ALG-1703 Amendment 2
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
KEYNOTES EXTRACTED from ARCHIBELS' RADAR V8.1
HOMEOPATHY - KEYNOTES FOR 341 DRUGS INFORMATION EXTRACTED FROM ARCHIBELS' RADAR/SYNTHESIS v8.1 ------------------------------------------------------------------------------------------------- # ABELMOSCHUS (abel.) Mind - IRRATIONAL FEAR OF ANIMALS agg. night. - Delirium with hallucinations. Generals - agg. Night. - amel. Eating small quantity. - Addison's disease. - Pernicious anemia. - Tetany. Food and drinks - Desire: Cold food and drinks. Head - Migraine. - Heavy feeling, as if in a vice. Eye/vision - Pain as from a nail. - Scotoma: spots before eyes with difficult vision. - Glaucoma. Detached retina. Ear/hearing - Difficult hearing on ascending stairs. Face - Paralysis, trembling lips and jaw. - Clenched jaw. - Pale, yellow; itching. Mouth - Salivation increased, with sensation of dryness. - Saliva thick, sticky. - Difficult speech. Throat/external throat - Swallowing difficult. - Pain sides throat on turning head. Stomach - Pain in pit of stomach. Respiration - Difficult. Chest - Tight feeling region of heart. - Palpitations with anxiety. Extremities - Trembling, weakness, paralysis; with edema. Dd Apis, Ars, Bell, Carc, Chin, Stram. # ABIES CANADENSIS (abies-c.) * Esp. digestive problems. Mind - Irritability, moody, peevish (Nux-v). Snappish. - Not as impatient or driven as nux-v. - Mental exhaustion. Dazed. Indifferent. Generalities - Chilly; as if blood were ice-water. - Wants to lie down. Lies with legs drawn up. Sluggishness not amel. by eating stimulating food. - agg. Right side. - amel. Pressure. Food and drinks - Desire: Coarse, indigestible food. - Aversion: Sour food. - agg.: Coarse food, tea. Head - Faint, drunken feeling. Stomach - GNAWING PAIN; GREAT APPETITE, TENDENCY TO OVEREAT. Faint feeling at epigastrium, ext. to head. - Distention agg. eating. Abdomen - Sensation as if RIGHT LUNG AND LIVER SMALL AND HARD. - Pain right hypochondrium, ext. to right scapula (Chel.). - Rumbling agg. eating. Rectum - Burning pain (constipation). -
WHO Drug Information Vol
WHO Drug Information Vol. 24, No. 4, 2010 World Health Organization WHO Drug Information Contents WHO Prequalification Sitaxentan: worldwide withdrawal 307 Programmes Sibutramine: suspension of sales 307 Sibutramine-containing medicines: WHO Prequalification of Medicines withdrawal 308 Programme: survey of service Testosterone transdermal patch: quality provided to manufacturers 293 withdrawal of extension of WHO initiates pilot prequalification of indication application 308 active pharmaceutical ingredients 297 Aliskiren/valsartan: withdrawal of New on-line database for WHO marketing authorization application 308 prequalified vaccines 298 Mometasone furoate/formoterol fumarate: withdrawal of marketing Safety and Efficacy Issues authorization application 309 EMA and US FDA extend confidentiality H1N1 influenza vaccine: narcolepsy 299 arrangements indefinitely 309 Statins: interstitial lung disease 299 Tocilizumab: risk of fatal anaphylaxis 300 Recent Publications, Pioglitazone: potential bladder cancer 301 Information and Events Angiotensin receptor blockers and US Government to share patents with cancer: safety review 301 Medicines Patent Pool 310 GnRH agonists, diabetes and cardio- Clinical trials and global medicines vascular disease 301 development 310 Gadolinium-based contrast agents: Evaluation of future nanomedicines 311 kidney dysfunction 302 Reporting on opioid inaccessibility 311 Lamotrigine: aseptic meningitis Tinzaparin sodium: renal Impairment in elderly 303 Consultation Documents Tamoxifen: drug interactions involving The -
Allergy to Pet: Differential Approaches to Selection 0F Specific Allergotherapy Prescription with Due Account of Component Studie
Quest Journals Journal of Medical and Dental Science Research Volume 3~ Issue 4 (2016) pp: 29-35 ISSN(Online) : 2394-076X ISSN (Print):2394-0751 www.questjournals.org Research Paper Allergy to Pet: Differential Approaches to Selection 0f Specific Allergotherapy Prescription With Due Account of Component Studie Zubchenko Svitlana, Sergii Yuryev Received 17 April, 2016; Accepted 31 May, 2016 © The author(s) 2015. Published with open access at www.questjournals.org ABSTRACT Introduction: One of the topical problems is allergy to home pets, viz. to cat and dog that occurs among adults at the rate of 5-15%. Aim: To choose an adequate therapy and to make the prognosis of its efficacy in patients with sensitization and clinical manifestations of allergy to cat and dog. Material and methods: 22 patients aged 16-36 have been studied. The diagnosis was verified on the basis of objective and subjective data, overall laboratory and instrumental tools, prick tests, general and specific IgE determination. The study of allergen components was made by immunofluorescence method ImmunoCAP. Results: According to the results of skin prick tests sensitization to cat was traced in 81.8% persons, of whom monosensitization was traced in 27.8%, association of cat allergens with other types of allergens – in 72.2%, most frequently this being – cat+dog. Higher levels of general ІgЕ were traced in 77.3% patients. Specific ІgЕ only to cat was traced in 16.6% ones, while the rest 83.4% of patients had specific ІgЕ to cat in the combination with different domestic allergens. Patients with major cat allergen Fel d 1 alone or in combination with minor allergen Fel d 2 were prescribed allergen immunotherapy with high/medium efficacy prognosis. -
Feeding Cats Egg Product with Polyclonal-Anti-Fel D1 Antibodies Decreases Environmental Fel D1 and Allergic Response: a Proof of Concept Study
Wedner et al., J Allergy Infect Dis Journal of Allergy and Infectious Diseases 2021; 2(1):1-8. Research Article Feeding cats egg product with polyclonal- anti-Fel d1 antibodies decreases environmental Fel d1 and allergic response: A proof of concept study H. James Wedner1,*, Tarisa Mantia1, Ebenezer Satyaraj2, Cari Gardner2, Noor Al-Hammadi3, Scott Sherrill2 1Clinical Research Center, Division of Abstract Allergy and Immunology, Washington University School of Medicine, St. Louis, Background: Cat allergens are a major contributor to environmental allergens’ overall burden, but efforts MO, USA to reduce cat allergens are often unsuccessful. 2Nestlé Purina Research, St. Louis, MO, Objective: To determine whether feeding cats a diet containing an egg product with anti-Fel d1 IgY USA would produce clinically relevant reductions in allergy symptoms of human subjects. 3Department of Biostatistics, Methods: Following a priming exposure to blankets used for cat bedding, human subjects were Washington University School of subsequently exposed to environmental chambers primed with blankets from cats fed either a control Medicine, St. Louis, MO, USA diet or a test diet containing an egg product with polyclonal anti-Fel d1 IgY. 8 cats: 5 neutered male and 3 spayed females were used. Total Nasal Symptom Score and Total Ocular Symptom Score were assessed at regular intervals. Subjects were randomly exposed to the control or test condition on the first exposure *Author for correspondence: and the opposite condition on the second exposure. Email: [email protected] Results: The levels of immunologically active Fel d1 in chambers with blankets from cats fed the test Received date: May 22, 2020 diet were lower than those from control cats, and human subjects exposed to this condition showed Accepted date: January 11, 2021 significantly lower Total Nasal Symptom Scores and improvement in some ocular symptoms. -
2018 Medicines in Development for Skin Diseases
2018 Medicines in Development for Skin Diseases Acne Drug Name Sponsor Indication Development Phase ADPS topical Taro Pharmaceuticals USA acne vulgaris Phase II completed Hawthorne, NY www.taro.com AOB101 AOBiome acne vulgaris Phase II (topical ammonia oxidizing bacteria) Cambridge, MA www.aobiome.com ASC-J9 AndroScience acne vulgaris Phase II (androgen receptor degradation Solana Beach, CA www.androscience.com enhancer) BLI1100 Braintree Laboratories acne vulgaris Phase II completed Braintree, MA www.braintreelabs.com BPX-01 BioPharmX acne vulgaris Phase II (minocycline topical) Menlo Park, CA www.biopharmx.com BTX1503 Botanix Pharmaceuticals moderate to severe acne vulgaris Phase II (cannabidiol) Plymouth Meeting, PA www.botanixpharma.com CJM112 Novartis Pharmaceuticals acne vulgaris Phase II (IL-17A protein inhibitor) East Hanover, NJ www.novartis.com clascoterone Cassiopea acne vulgaris Phase III (androgen receptor antagonist) Lainate, Italy www.cassiopea.com Medicines in Development: Skin Diseases ǀ 2018 Update 1 Acne Drug Name Sponsor Indication Development Phase CLS001 Cutanea acne vulgaris Phase II (omiganan) Wayne, PA www.cutanea.com DFD-03 Promius Pharma acne vulgaris Phase III (tazarotene topical) Princeton, NJ www.promiuspharma.com DMT310 Dermata Therapeutics moderate to severe acne vulgaris Phase II (freshwater sponge-derived) San Diego, CA www.dermatarx.com finasteride Elorac severe nodulocystic acne Phase II (cholestenone 5-alpha Vernon Hills, IL www.eloracpharma.com reductase inhibitor) FMX101 Foamix moderate to severe -
Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG . -
Allergic to Cats
Good Mews Wisdom Good Mews Animal Foundation 736 Johnson Ferry Road, Ste. A-3 Marietta, Georgia 30068 (770) 499-CATS (2287) www.goodmews.org Owner Allergic For those who suffer from an allergy to cats, the key to living with a feline is to manage the symptoms. Does interacting with your feline companion bring tears of agony instead of tears of joy? In addition to itchy, watery eyes, do you exhibit other symptoms such as runny nose, rash, hives, coughing, sneezing, wheezing, asthma or other breathing problems? Like an estimated 2 percent of the U.S. population, you suffer from an allergy to cats and, like about one- third of those people, you've chosen to keep your cat companion. But at what cost? Contrary to popular belief, cat hair itself is not allergenic. The cause of allergy to cats is a protein called Fel d 1 emanating from sebum found in the sebaceous glands of cats. The protein attaches itself to dried skin, called dander, that flakes off and floats through the air when cats wash themselves. Although you may never be able to eliminate all your allergy symptoms, following these suggestions can help make living with your cat a more enjoyable experience. 1. Designate your bedroom as a cat-free zone. Begin your program of allergen reduction by washing bedding, drapes and pillows. Better yet, replace them. Use plastic covers that are designed to prevent allergens from penetrating on your mattress and pillows. Allergen-proof covers are available from medical supply outlets. Don't expect results overnight. Cat allergens are one-sixth the size of pollens, and it may take months to reduce them significantly. -
Crth2: Can Residence Time Help ?
CRTh2: Can Residence Time Help ? RSC-SCI Cambridge Medicinal Chemistry Symposium Churchill College, Cambridge 8-11 September 2013 Rick Roberts Almirall Introduction Paul Ehrlich, The Lancet (1913), 182, 445 “A substance will not work unless it is bound” 100 years on: “What a substance does may depend on how long it is bound” 2 In a nutshell …. Introduction “Applications of Binding Kinetics to Drug Discovery” D. Swinney, Pharm. Med. (2008), 22, 23-34 3 Energetic concept of Residence Time kon Standard model [R] + [L] [RL] k unbound off bound Energy ‡ Binding process (kon) is (R·L) determined by the energy barrier Ea E Ligand concentration a Unbinding process (koff) is determines the number of Ed determined by the energy attempts to get over this barrier Ed barrier [R] + [L] G = Ed -Ea [RL] Reaction coordinate Potency (Ki) is determined by the difference in these energies koff Ki = kon 4 K , k , k i on off -1 -1 kon M s Potency (nM) vs kon vs koff Very fast association 108 10 1 0.1 0.01 0.001 107 100 10 1 0.1 0.01 0.001 fast association 106 1000 100 10 1 0.1 0.01 0.001 105 10 M 1000 100 10 1 0.1 0.01 0.001 slow association 104 10 M 1000 100 10 1 0.1 0.01 Very slow association 103 10 M 1000 100 10 1 0.1 “inactive” 102 10 M 1000 100 10 1 10 10-1 10-2 10-3 10-4 10-5 10-6 10-7 s-1 koff Energy A simple binding measurement gives no clue to how fast the association and dissociation are (R·L)‡ Very slow associating compounds that are very slow dissociating (R·L)‡ slow associating compounds that are slow dissociating Are all fast associating compounds -
Cat Allergy It's Everywhere!
CAT ALLERGY IT'S EVERYWHERE! Jeffrey Marcus, M.D., FACS. Why are some people allergic to cats? When people are allergic, it's because they react to specific chemicals which are called "antigens." In the case of cats, the major antigen that causes people to have allergic reactions has been identified. This chemical is present in the cat's saliva and in the glands in the skin. When the cat preens itself, the antigen is deposited on the cat's skin and hair. Where can you find the cat antigen? Studies have shown that you don't have to be near a cat to find cat allergen. It can be found in such improbable places as stores in shopping malls and in hospital corridors. One investigator found that about 31% of American homes have one or more cats. It appears that the way that the antigen gets distributed is on the clothing of cat owners. After a person holds a cat for 5 minutes, the shirt they are wearing will have 100 times the amount of cat antigen needed to cause wheezing in a person who has asthma due to cats. Cat antigen is found not only in homes without cats, but also is found widespread in our environment, including in public places where cats are not permitted. This suggests that clothing disperses the antigen casually. How can you tell if you are allergic to cats? People who are extremely allergic (such as many asthmatics) know very well that they are sensitive to cats. They usually have an immediate reaction when around the animals. -
Solubility Challenges: Unlocking a Drug’S Potential JULY 2015 Pharmtech.Com
JULY 2015 Volume 39 Number 7 Volume 39 Number 7 Cleaning Stability Tablet Count PLUS: Validation of Biologics in Packaging PHARMACEUTICAL TECHNOLOGY Solubility Challenges: Unlocking a Drug’s Potential JULY 2015 2015 JULY PharmTech.com PEER-REVIEWED Using In-Situ Gelling to Optimize Opthalmic Drug Delivery DRUG DELIVERY OPERATIONAL EXCELLENCE API SYNTHESIS & MANUFACTURING Targeting Drugs to the Colon Data Integrity Continuous API Synthesis magentablackcyanyellow ES639585_PT0715_cv1.pgs 07.07.2015 20:54 ADV magentablackcyanyellow ES639144_PT0715_CV2_FP.pgs 07.06.2015 20:46 ADV INTRODUCING Vion IMS QTof When you’re up against complex samples, sometimes resolution and accurate mass aren’t enough to give you all the information you need. Enter Vion IMS QTof with Collision Cross Section (CCS). A new mass spectrometer that brings ion mobility to the benchtop like never before. Now the analytes you didn’t know were there have nowhere to hide. To learn more, visit waters.com/VION PHARMACEUTICAL n HEALTH SCIENCES n FOOD n ENVIRONMENTAL n CHEMICAL MATERIALS magentablackcyanyellow ES639166_PT0715_003_FP.pgs 07.06.2015 20:46 ADV EDITORIAL SALES Editorial Director Rita Peters [email protected] Publisher Mike Tracey [email protected] Senior Editor Agnes Shanley [email protected] Director of Sales Paul Milazzo [email protected] Managing Editor Susan Haigney [email protected] Mid-West Sales Manager Irene Onesto [email protected] Science Editor Adeline Siew, PhD [email protected] East Coast Sales Manager Joel Kern [email protected] -
Prostanoid Receptors (Version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database
IUPHAR/BPS Guide to Pharmacology CITE https://doi.org/10.2218/gtopdb/F58/2019.5 Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database Richard M. Breyer1, Lucie Clapp2, Robert A. Coleman3, Mark Giembycz4, Akos Heinemann5, Rebecca Hills6, Robert L. Jones7, Shuh Narumiya8, Xavier Norel9, Roy Pettipher10, Yukihiko Sugimoto11, Mohib Uddin12, David F. Woodward13 and Chengcan Yao6 1. Vanderbilt University, USA 2. University College London, UK 3. Pharmagene Laboratories, UK 4. University of Calgary, Canada 5. Otto Loewi Research Center (for Vascular Biology, Immunology and Inflammation), Austria 6. University of Edinburgh, UK 7. University of Strathclyde, UK 8. Kyoto University Faculty of Medicine, Japan 9. Laboratory for Vascular Translational Science, France 10. Atopix Therapeutics Ltd, UK 11. Kumamoto University, Japan 12. AstraZeneca, Sweden 13. Allergan plc, USA Abstract Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [659]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are often replaced by cicaprost and U46619, respectively, in receptor characterization studies. Contents This is a citation summary for Prostanoid receptors in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links. GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. -
Airborne Allergens
Chapter 2 Airborne Allergens Olga Ukhanova and Evgenia Bogomolova Additional information is available at the end of the chapter http://dx.doi.org/10.5772/59300 1. Introduction A huge number of substances of various origin forming atmospheric aerosols constantly circulates in the atmospheric air (Table 1). One of the most important components of such aerosols are airborne allergens. Airborne allergens are substances of biological origin, which getting into the human body promote the induction of the immune response with the subse‐ quent development of an allergic disease. Allergic reaction is directly caused by proteins and glycoproteins forming the airborne allergen. Type of particles Diameter (mkm) Smoke, smog 0, 001-0, 1 Dust 0, 1 Bacteria 0, 3-10 Fungi spores / conidia 1, 0-100, 0 Algae / seaweed 0, 5 Fragments of lichen 1, 0 Protozoa 2, 0 Spores of mosses 6, 0-30, 0 Pollen 10, 0-100, 0 Fragments of plants and animals, seeds, insects >100 Table 1. The components of the atmospheric aerosols and their size [4]. © 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and eproduction in any medium, provided the original work is properly cited. 36 Allergic Diseases - New Insights More than 15 million people in Europe suffer from allergic rhinitis, conjunctivitis, bronchial asthma, atopic dermatitis and food allergy. Climatic and geographic features of the Russian Federation (its Northern and Southern parts, as well as European and Asian territories) contribute to a different sickness rate among the population [1, 2].